CDK9-IN-7
CAT:
804-HY-126251-05
Size:
50 mg
Price:
Ask
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No
CDK9-IN-7
- CAS Number: 2369981-71-3
- UNSPSC Description: CDK9-IN-7 (compound 21e) is a selective, highly potent, and orally active CDK9/cyclin T inhibitor (IC50=11 nM), which exhibits more potent over other CDKs (CDK4/cyclinD=148 nM; CDK6/cyclinD=145 nM). CDK9-IN-7 shows antitumor activity without obvious toxicity. CDK9-IN-7 induces NSCLC cell apoptosis, arrests the cell cycle in the G2 phase, and suppresses the stemness properties of NSCLC[1].
- Target Antigen: Apoptosis; CDK
- Type: Reference compound
- Related Pathways: Apoptosis;Cell Cycle/DNA Damage
- Field of Research: Cancer
- Assay Protocol: https://www.medchemexpress.com/cdk9-in-7.html
- Purity: 98.05
- Solubility: DMSO : 62.5 mg/mL (ultrasonic)
- Smiles: O=C(N(C)C)C1=CC2=CN=C(NC3=CC=C(NC(CCCCCCCN=C=S)=O)C=C3)N=C2N1C4CCCC4
- Molecular Weight: 547.71
- References & Citations: [1]Wang X, et al. Novel cyclin-dependent kinase 9 (CDK9) inhibitor with suppression of cancer stemness activity against non-small-cell lung cancer. Eur J Med Chem. 2019 Jul 25;181:111535.
- Shipping Conditions: Room Temperature
- Storage Conditions: -20°C, 3 years; 4°C, 2 years (Powder)
- Clinical Information: No Development Reported